Abstract 1669P
Background
Studies have shown that patients with cervical intraepithelial neoplasia (CIN) linked to human papillomavirus (HPV) experience shame and/or guilt due to the association of HPV with sexual transmission. Likewise, such feelings were also reported by cervical cancer (CC) patients. Understanding the similarities or differences in the relationship between guilt, shame, and quality of life (QoL) among these two groups might shed light on effective psychosocial interventions.
Methods
The study employed a cross-sectional design. Patients diagnosed with CIN (n=105, 11.42% CIN 1, 15.23% CIN 2, 58.09% CIN 3, 8.57% unknown) and CC (n=87, 16.09% stage 1, 17.24% stage 2, 36.78% stage 3, 8.04% stage 4, 8.04% were diagnosed with CIN that later progressed, 8.04% were uncertain about their stage at diagnosis, 5.74% unknown) who were recruited through social networks specific to CIN and CC patients completed self-report questionnaires assessing demographic information, medical history, QoL, and feelings of shame and guilt.
Results
The preliminary results revealed a significant negative association between both guilt and shame and QoL in both groups. However, no significant difference in QoL was found between CIN and CC patients (57.12, 52.26 respectively, p=0.1). Additionally, a significant higher level of guilt was reported by CIN patients (13.42) compared to CC patients (10.26) (d=0.58, p=0.0001). There was no significant difference in shame reported by CIN patients compared to CC patients (12.8, 11.37 respectively, p=0.07).
Conclusions
The findings underscore the detrimental role of shame and guilt in the perception of QoL of patients with CIN and CC. Addressing these negative feelings through targeted interventions may be crucial for improving overall well-being in these populations and enhancing their coping mechanisms. Further research involving a larger sample size may provide deeper insights into the differences and similarities between CIN and CC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar - Israel Women's Cancer Association (RA) in collaboration with Ariel University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11